Share This Article:

Prognostic Value of Neutrophil Lymphocyte Ratio in Second Line Advanced Malignant Pleural Mesothelioma

Abstract Full-Text HTML Download Download as PDF (Size:276KB) PP. 717-722
DOI: 10.4236/jct.2014.57080    3,183 Downloads   3,926 Views   Citations

ABSTRACT

Background: Malignant pleural mesothelioma is a lethal disease and hence the strong need for identifying new prognostic factors. Methods: This is a retrospective study including all eligible patients with advanced malignant pleural mesothelioma (MPM) presenting to National Cancer Institute, Cairo University. Neutrophil lymphocyte (N/L) ratio was assessed before second line chemotherapy. 2.5 was used as the cutoff point. Endpoints were the assessment of correlation between N/L ratio and clinical response (CR), progression free survival (PFS) and overall survival (OS). Results: 52 patients (19 stage III and 33 stage IV) MPM were included and followed up during the period from July 2009 till November 2012 with a median follow-up period of 2.6 months. 87.5% of patients with N/L ratio > 2.5 showed progressive disease versus 91.7% in patients with N/L ratio < 2.5 (P-value = 0.66). 6-month PFS was 11% for patients with N/L ratio > 2.5 versus 14% for patients with N/L ratio < 2.5 (P-value = 0.001). 6-month OS was 72% for patients with N/L ratio > 2.5 versus 66% for patients with N/L ratio < 2.5 (P-value = 0.4). Conclusion: N/L ratio is a potential prognostic marker for advanced MPM treated with second line chemotherapy.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

El Bastawisy, A. , Yahia, M. , Rahman, A. and Gaafar, R. (2014) Prognostic Value of Neutrophil Lymphocyte Ratio in Second Line Advanced Malignant Pleural Mesothelioma. Journal of Cancer Therapy, 5, 717-722. doi: 10.4236/jct.2014.57080.

References

[1] Price, B. and Ware, A. (2009) Time Trend of Mesothelioma Incidence in the United States and Projection of Future Cases: An Update Based on SEER Data for 1973 through 2005. Critical Reviews in Toxicology, 39, 576-588. http://dx.doi.org/10.1080/10408440903044928
[2] Pelucchi, C., Malvezzi, M., La Vecchia, C., et al. (2004) The Mesothelioma Epidemic in Western Europe: An Update. British Journal of Cancer, 90, 1022-1024.
http://dx.doi.org/10.1038/sj.bjc.6601638
[3] Curran, D., Sahmoud, T., Therasse, P., van Meerbeeck, J., Postmus, P.E. and Giaccone, G. (1998) Prognostic Factors in Patients with Pleural Mesothelioma: The European Organization for Research and Treatment of Cancer Experience. Journal of Clinical Oncology, 16, 145-152.
[4] Herndon, J.E., Green, M.R., Chahinian, A.P., Corson, J.M., Suzuki, Y. and Vogelzang, N.J. (1998) Factors Predictive of Survival among 337 Patients with Mesothelioma Treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest, 113, 723-731.
http://dx.doi.org/10.1378/chest.113.3.723
[5] Wang, X. (2014) Neutrophil to Lymphocyte Ratio in Relation to Risk of All-Cause Mortality and Cardiovascular Events among Patients Undergoing Angiography or Cardiac Revascularization: A Meta-Analysis of Observational Studies. Atherosclerosis, 234, 206-213.
http://dx.doi.org/10.1016/j.atherosclerosis.2014.03.003
[6] Wang, J. (2014) The Clinical Significance of Tumor-Infiltrating Neutrophils and Neutrophil-to-CD8+ Lymphocyte Ratio in Patients with Resectable Esophageal Squamous Cell Carcinoma. Journal of Translational Medicine, 12, 7. http://dx.doi.org/10.1186/1479-5876-12-7
[7] Xue, P. (2014) Neutrophil-to-Lymphocyte Ratio for Predicting Palliative Chemotherapy Outcomes in Advanced Pancreatic Cancer Patients. Cancer Medicine, 3, 406-415.
http://dx.doi.org/10.1002/cam4.204
[8] Jarnicki, A., Putoczki, T. and Ernst, M. (2010) Stat3: Linking Inflammation to Epithelial Cancer—More than a “Gut” Felling? Cell Division, 5, 14. http://dx.doi.org/10.1186/1747-1028-5-14
[9] Byrne, M.J. and Nowak, A.K. (2004) Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma. Annals of Oncology, 15, 257-260. http://dx.doi.org/10.1093/annonc/mdh059
[10] Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N. and Clarke, S. (2010) High Blood Neutrophilto-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy. Clinical Cancer Research, 16, 5805-5813.
http://dx.doi.org/10.1158/1078-0432.CCR-10-2245
[11] Sarraf, K.M., Belcher, E., Raevsky, F., Nicholson, A.G., Goldstraw, P. and Lim, E. (2009) Neutrophil/Lymphocyte Ratio and Its Association with Survival after Complete Resection in Non-Small Cell Lung Cancer. Journal of Thoracic and Cardiovascular Surgery, 137, 425-428.
http://dx.doi.org/10.1016/j.jtcvs.2008.05.046
[12] Walsh, S.R., Cook, E.J., Goulder, F., Justin, T.A. and Keeling, N.J. (2005) Neutrophil-Lymphocyte Ratio as a Prognostic Factor in Colorectal Cancer. Journal of Surgical Oncology, 91, 181-184.
http://dx.doi.org/10.1002/jso.20329
[13] Kishi, Y., Kopetz, S., Chun, Y., Palavecino, M., Abdalla, E.K. and Vauthey, J.N. (2009) Blood Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Colorectal Liver Metastases Treated with Systemic Chemotherapy. Annals of Surgical Oncology, 16, 614-622.
http://dx.doi.org/10.1245/s10434-008-0267-6
[14] Halazun, K.J., Aldoori, A., Malik, H.Z., Al-Mukhtar, A., Prasad, K.R., Toogood, G.J., et al. (2008) Elevated Preoperative Neutrophil to Lymphocyte Ratio Predicts Survival Following Hepatic Resection for Colorectal Liver Metastases. European Journal of Surgical Oncology, 34, 55-60.
http://dx.doi.org/10.1016/j.ejso.2007.02.014
[15] Gomez, D., Morris-Stiff, G., Toogood, G., Lodge, J.P. and Prasad, K.R. (2008) Impact of Systemic Inflammation on Outcome Following Resection for Intrahepatic Cholangiocarcinoma. Journal of Surgical Oncology, 97, 513-518. http://dx.doi.org/10.1002/jso.21001
[16] Meniawy, T., Creaney, J., Lake, R. and Nowak, A. (2013) Existing Models, but Not Neutrophil-to-Lymphocyte Ratio, Are Prognostic in Malignant Mesothelioma. British Journal of Cancer, 109, 1813-1820. http://dx.doi.org/10.1038/bjc.2013.504
[17] Pinato, D., Stavraka, C., Flynn, M., Forster, M., O’Cathail, S., Seckl, M., Kristeleit, R., Olmos, D., Turnbull, S. and Blagden, S. (2014) An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials. PLoS ONE, 9, Article ID: e83279. http://dx.doi.org/10.1371/journal.pone.0083279

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.